Microbiotix, Inc

Microbiotix, Inc. is a clinical-stage biopharmaceutical company that discovers and develops small molecule drugs targeting serious infectious diseases, including multi-drug resistant pathogens. The company's lead therapeutic candidate, MBX-400, is a nucleoside analog dual DNA polymerase/kinase inhibitor in development for human cytomegalovirus (CMV) treatment and has completed Phase 1 clinical testing.